While 5-FU has been the backbone of sporadic CRC treatment since 1960, advances in molecular comprehension, including the role of MMR deficiencies in response to therapy, brought to light a mechanism for 5-FU resistance. The gene discussed is MRC1; the disease is colorectal carcinoma.